You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood conditions

Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban

  • Technology appraisal guidance
  • Reference number: TA697
  • Published:  12 May 2021
  • Last updated:  15 January 2025
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History
Download guidance (PDF)
  • Overview
  • 1 Recommendations
  • 2 Information about andexanet alfa
  • 3 Committee discussion
  • 4 Implementation
  • 5 Recommendations for research
  • 6 Appraisal committee members and NICE project team
  • Update information

Update information

January 2025: Recommendation 1.2 was updated and replaced by NICE's technology appraisal guidance on andexanet alfa for reversing anticoagulation in people with intracranial haemorrhage (terminated appraisal).

ISBN: 978-1-4731-6733-9


Previous page 6 Appraisal committee members and NICE project team
Back to top